Source 1review2022International Journal of Molecular Sciences
Toolkit/human opsins
human opsins
Taxonomy: Mechanism Branch / Component. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Human opsins are protein domains used as optogenetic tools in visual restoration strategies. The supplied evidence indicates that applying human opsins can improve light sensitivity and wavelength sensitivity in optogenetic systems, and places these tools within ongoing clinical translation for retinal therapy.
Usefulness & Problems
Why this is useful
Human opsins are useful in optogenetic therapy design because they are associated with improved light sensitivity and wavelength sensitivity, two core performance parameters for light-driven control in the retina. The evidence specifically situates them in visual restoration efforts where optogenetic tool choice is a key design element.
Source:
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Problem solved
This tool helps address the challenge of achieving effective optical responsiveness for visual restoration, particularly by improving sensitivity to light intensity and wavelength. The supplied evidence does not provide more specific molecular or cell-type-resolved problem definitions beyond retinal optogenetic therapy design.
Source:
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Problem links
Need precise spatiotemporal control with light input
DerivedHuman opsins are protein domains used as optogenetic tools, with reported improvements in light sensitivity and wavelength sensitivity when applied in optogenetic systems. The supplied evidence places them in the context of optogenetic therapy for visual restoration.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Component: A low-level protein part used inside a larger architecture that realizes a mechanism.
Target processes
No target processes tagged yet.
Input: Light
Implementation Constraints
cofactor dependency: requires exogenous cofactorencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: spectral hardware requirementoperating role: actuatorswitch architecture: single chain
The evidence indicates that use of human opsins occurs within optogenetic therapy designs that also require selection of target retinal cells and gene delivery systems. No specific construct design, chromophore requirement, expression system, promoter, or vector details are provided in the supplied material.
The supplied evidence does not identify which human opsins were used, their spectral peaks, signaling properties, kinetics, or quantitative performance gains. It also does not provide independent comparative data, construct architectures, or direct trial results for any specific human opsin-based tool.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Approval Evidence
1 source6 linked approval claimsfirst-pass slug human-opsins
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by ... applying human opsins
Source:
clinical translation statussupports
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Source:
design factor importancesupports
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Source:
engineering improvementsupports
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Source:
genotype independencesupports
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Source:
optimization needsupports
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Source:
therapeutic promisesupports
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Source:
Comparisons
Source-backed strengths
The cited evidence attributes improved light sensitivity and wavelength sensitivity to the application of human opsins in optogenetic systems. Human opsins are also discussed in the context of a field with multiple ongoing clinical trials for visual restoration, supporting translational relevance of this tool class.
Source:
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Source:
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Compared with engineered soluble photoactivated guanylate cyclases
human opsins and engineered soluble photoactivated guanylate cyclases address a similar problem space.
Shared frame: same top-level item type; shared mechanisms: light activation; same primary input modality: light
Relative tradeoffs: looks easier to implement in practice; may avoid an exogenous cofactor requirement.
Compared with mammalian rod opsin
human opsins and mammalian rod opsin address a similar problem space.
Shared frame: same top-level item type; shared mechanisms: light activation; same primary input modality: light
Relative tradeoffs: looks easier to implement in practice; may avoid an exogenous cofactor requirement.
Compared with melanopsin
human opsins and melanopsin address a similar problem space.
Shared frame: same top-level item type; shared mechanisms: light activation; same primary input modality: light
Relative tradeoffs: appears more independently replicated; looks easier to implement in practice; may avoid an exogenous cofactor requirement.
Ranked Citations
- 1.